TY  - CHAP
M1  - Book, Section
TI  - Immunotherapy: Past, Present and Future
A1  - Hill, Samuel L.
A1  - Johnson, Peter W.M.
A2  - Board, Ruth E.
A2  - Nathan, Paul
A2  - Newsom-Davis, Tom
A2  - Papa, Sophie
A2  - Johnson, Peter
Y1  - 2019
N1  - 
T2  - Problem Solving in Cancer Immunotherapy
AB  - The  intuitive  appeal  of  eliciting  an  effective  immune  response  against  cancers  has  long  been  recognized  but,  until  quite  recently,  rarely  fulfilled.  At  the  end  of  the  19th  century,  William  Coley,  a  New  York  sarcoma  surgeon,  noted  some  tumour  regressions  in  cancer  patients  infected  with  streptococci,  by  provoking  an  immune  response.1  But  such  responses  proved  hard  to  replicate  and  his  treatments  quickly  fell  out  of  favour.  The  idea,  however,  remained  potent.  Occasional  instances  of  spontaneous  tumour  regression2,3  or  prolonged  dormancy  suggested  some  form  of  ‘host  restraint’,  and  a  number  of  clinical  successes  kept  the  field  of  immunotherapy  alive,  despite  the  many  failed  attempts  at  treatment.  
SN  - 
PB  - EBN Health
CY  - New York, NY
Y2  - 2021/01/27
UR  - hemonc.mhmedical.com/content.aspx?aid=1160632587
ER  -